Edition:
United States

Rosetta Genomics Ltd (ROSG.OQ)

ROSG.OQ on NASDAQ Stock Exchange Capital Market

0.61USD
9:48am EST
Change (% chg)

$-0.03 (-4.01%)
Prev Close
$0.64
Open
$0.64
Day's High
$0.64
Day's Low
$0.61
Volume
1,200
Avg. Vol
46,729
52-wk High
$7.08
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

Rosetta Genomics suspends 2017 revenue and unit guidance for Reveal‍​
Tuesday, 10 Oct 2017 09:56am EDT 

Oct 10 (Reuters) - Rosetta Genomics Ltd ::Says suspends its previously announced 2017 revenue and unit guidance for Reveal - SEC filing ‍​.Says intends to update its Reveal revenue and unit guidance by year-end 2017.  Full Article

Rosetta Genomics prices public offering of 1.95 mln units at $1.40/unit
Friday, 4 Aug 2017 08:55am EDT 

Aug 4 (Reuters) - Rosetta Genomics Ltd :Rosetta genomics says priced public offering of 1.95 million units at effective purchase price of $1.40 per unit‍​.  Full Article

Morgan Stanley reports 5.1 pct passive stake in Rosetta Genomics
Friday, 2 Jun 2017 04:16pm EDT 

June 2 (Reuters) - Morgan Stanley :Morgan stanley reports 5.1 percent passive stake in Rosetta Genomics as of May 23, 2017 - ‍​SEC filing.  Full Article

Rosetta Genomics announces 1-for-12 reverse stock split
Thursday, 16 Mar 2017 12:02pm EDT 

Rosetta Genomics Ltd : Rosetta Genomics announces 1-for-12 reverse stock split . Says ordinary shares will begin trading on a split-adjusted basis on March 17, 2017 .Reverse stock split was approved by its shareholders at an extraordinary general meeting of shareholders of company held earlier.  Full Article

Rosetta Genomics reports preliminary Q4 rosettagx reveal results
Wednesday, 8 Feb 2017 09:19am EST 

Rosetta Genomics Ltd - : Rosetta Genomics reports preliminary rosettagx reveal(tm) financial results for the 2016 fourth quarter and year . Reiterates 2017 rosettagx reveal revenue guidance of between $4 million and $5 million . Says preliminary reveal revenue for Q4 of 2016 was approximately $390,000 . During Q4 of 2016, received 423 reveal orders, a 39% increase compared with 305 reveal units received in Q3 of 2016 . Expects to process between 2,500 and 3,500 reveal units during year 2017 .Says reveal revenue for year ended Dec 31, 2016 was approximately $850,000.  Full Article

Rosetta Genomics files for resale of up to 15.5 mln of co's ordinary shares by selling stockholders
Thursday, 8 Dec 2016 04:22pm EST 

Rosetta Genomics Ltd :Rosetta Genomics Ltd files for resale, from time to time, of up to 15.5 million of co's ordinary shares by selling stockholders - SEC filing.  Full Article

Rosetta Genomics fortifies intellectual property portfolio with two new patent allowances
Monday, 3 Oct 2016 08:00am EDT 

Rosetta Genomics Ltd : Rosetta genomics fortifies intellectual property portfolio with two new patent allowances for its novel microrna platform technology . Allowed korean patent claims method for diagnosing various cancers, using expression profile of hsa-mir-192, hsa-mir-200c, hsa-mir-193a .Received a notice of allowance from kipo for korean patent application no. 2010-7007495.  Full Article

Rosetta Genomics enters distribution agreement for RosettaGX Reveal in Israel with Rhenium
Thursday, 29 Sep 2016 10:54am EDT 

Rosetta Genomics Ltd : Rosetta genomics enters distribution agreement for rosettagx reveal(tm) in israel with rhenium . Rosetta genomics enters distribution agreement for rosettagx reveal(tm) in israel with rhenium . Rosetta genomics ltd says thyroid cancer diagnostic assay will be covered by israel's largest health insurance company .Under terms of agreement, rhenium's exclusivity is contingent on rhenium meeting certain volume commitments.  Full Article

Rosetta Genomics Q2 non-gaap loss per share $0.15 excluding items
Monday, 26 Sep 2016 04:05pm EDT 

Rosetta Genomics Ltd : Rosetta genomics reports 2016 second quarter financial results . Q2 loss per share $0.16 . Q2 revenue rose 23 percent to $2.4 million . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Q2 non-gaap loss per share $0.15 excluding items ."in q3 we expect approximately 300 reveal orders with gross billings of approximately $900,000".  Full Article

Rosetta Genomics gets notice of rescission of conditional approval from New York State Department of Health for 4 of co's Allele-specific PCR-based assays
Monday, 22 Aug 2016 05:06pm EDT 

Rosetta Genomics Ltd : Got notice of rescission of conditional approval from new york state department of health for 4 of co's Allele-specific PCR-based assays . "Confident" it will be able to address concerns raised by Nysdoh, plans to resubmit for nysdoh approval as soon as possible-sec filing .In the interim, the company will not process samples for co’s Allele-specific PCR-based assays from patients in New York.  Full Article